Table 7.
The top concordant upregulated and downregulated genes in alveolar/bronchiolar carcinomas (ABCs) from B6C3F1/N mice exposed to Antimony trioxide for 2 years and human non-small cell lung cancer as determined by Illumina BaseSpace™ Correlation Engine. Corresponding genes, if applicable, in spontaneously arising ABCs from B6C3F1/N mice are shown for comparison.
| Gene | Description | Mouse CMD ABCs | Mouse Spont. ABCs | Human NSCLC | Known relevance to cancer |
|---|---|---|---|---|---|
|
| |||||
| Top twenty up-regulated genes | |||||
| Dlk1 | delta-like 1 homolog (Drosophila) | 209.864 | - | 1.67 | Overexpression promotes lung cancer cell invasion 44 |
| Tmem27 | transmembrane protein 27 | 203.919 | - | 2.18 | Role in cancer unclear |
| Bpifa1 (Lunx) | BPI fold containing family A, member 1 | 86.890 | 186.552 | 1.91 | Expression is significantly higher in NSCLC vs. non-cancerous tissue 87 |
| Ros1 | Ros1 proto-oncogene | 34.188 | 32.183 | 2.63 | Gene rearrangements occurs in approximately 1–2% of NSCLC 88 |
| Trpv6 | transient receptor potential cation channel, subfamily V, member 6 | 29.483 | 20.227 | 1.31 | Trpv6 and Trpv5 expression are reduced in in tumor issues of NSCLC patients 89 |
| Bcl2l15 | BCLl2-like 15 | 29.296 | - | 5.24 | Role in cancer unclear |
| Sertad4 | SERTA domain containing 4 | 29.229 | 35.867 | 1.63 | Role in cancer unclear |
| Sox9 | SRY-box containing gene 9 | 25.855 | 20.302 | 4.11 | Promotes epithelial–mesenchymal transition in NSCLC; 90 possible biomarker for NSCLC 91 |
| Cldn2 | claudin 2 | 23.537 | 23.379 | 4.00 | Promote promatrix metalloproteinases, involved in epithelial-mesenchymal transition 92 |
| Pkhd1 | polycystic kidney and hepatic disease 1 | 18.251 | 6.152 | 1.73 | Role in cancer unclear |
| Pthlh | parathyroid hormone-like peptide | 18.096 | 20.908 | 1.22 | Mediates lung metastasis of KRAS-mutated colorectal cancer cells 93 |
| S100a14 | S100 calcium binding protein A14 | 17.717 | 7.285 | 1.86 | Expressed in a subset of human lung adenocarcinomas 94 |
| Arg2 | arginase type II | 16.942 | 22.408 | 1.52 | Significantly expressed in human small cell lung cancers |
| Stk39 | serine/threonine kinase 39 | 15.619 | 12.633 | 3.08 | Function as tumor oncogene in NSCLC 95 |
| Bex2 | brain expressed X-linked 2 | 14.330 | - | 1.74 | Promotes proliferation of glioblastoma cells 96 and colorectal cancer cells 97 |
| Nipal1 | NIPA-like domain containing 1 | 12.989 | 8.263 | 1.46 | Highly expressed in oral squamous cell carcinoma, possible oncogene 98 |
| Zfp618 | zinc fingerprotein 618 | 12.774 | - | 1.27 | Role in cancer unclear |
| Celf4 | CUGBP, Elav-like family member 4 | 12.574 | 6.927 | 1.27 | Role in cancer unclear |
| Slc15a1 | solute carrier family 15 (oligopeptide transporter), member 1 | 12.192 | 11.604 | 1.46 | Role in cancer unclear |
| Slc15a2 | solute carrier family 15 (H+/peptide transporter), member 2 | 11.443 | 9.180 | 1.42 | Role in cancer unclear |
| Top twenty down-regulated genes | |||||
| Ogn | osteoglycin | −170.083 | −126.005 | −8.21 | Tumor suppressing role in breast 53 and colorectal cancer 54 |
| Gpm6a | glycoprotein m6a | −145.801 | −170.789 | −28.3 | Role in cancer unclear |
| Mfap4 | microfibrillar-associated protein 4 | −89.389 | −88.929 | −6.37 | Involved in cell adhesion, potential tumor suppressor 55 |
| Scn7a | sodium channel, voltage-gated, type VII, alpha | −83.597 | −68.427 | −4.90 | Significantly associated with survival in lung cancer patients 99 |
| 1110017D15Rik | RIKEN cDNA 1110017D15 gene | −61.358 | - | −2.50 | Role in cancer unclear |
| 4833427G06Rik | RIKEN cDNA 4833427G06 gene | −60.671 | - | −2.02 | Role in cancer unclear |
| Pcolce2 | procollagen C-endopeptidase enhancer 2 | −56.017 | −28.611 | −7.72 | Role in cancer unclear |
| Tmem100 | transmembrane protein 100 | −53.002 | −57.658 | −24.9 | Potential tumor suppressor in human NSCLC 100 |
| Cyp4b1 | cytochrome P450, family 4, subfamily b, polypeptide 1 | −51.096 | −28.929 | −4.80 | Downregulated in human NSCLC and other lung tumors 101 |
| Fmo3 | flavin containing monooxygenase 3 | −49.629 | −43.592 | −2.66 | Role in cancer unclear |
| Ntrk2 | neurotrophic tyrosine kinase, receptor, type 2 | −37.760 | −39.431 | −2.52 | Significantly downregulated in lung adenocarcinoma 102 |
| AU021034 | expressed sequence AU021034 | −37.132 | - | −2.71 | Role in cancer unclear |
| Efcab1 | EF hand calcium binding domain 1 | −35.704 | −30.059 | −1.83 | Role in cancer unclear |
| Tubb1 | tubulin, beta 1 class VI | −34.052 | −34.886 | −3.00 | Role in cancer unclear |
| Dpt | dermatopontin | −33.766 | −18.368 | −4.16 | Overexpression of Dpt suppresses hepatocellular carcinoma cell migration 103 |
| Inmt | indolethylamine N-methyltransferase | −31.569 | −27.623 | −3.55 | Role in cancer unclear |
| Figf | c-fos induced growth factor | −30.376 | - | −12.7 | Downregulated in Lung squamous cell carcinoma 104 |
| Ppbp | pro-platelet basic protein | −28.726 | −19.302 | −10.3 | Role in cancer unclear |
| Hpgd | hydroxyprostaglandin dehydrogenase 15 (NAD) | −28.194 | −25.948 | −2.38 | Tumor suppressor function, overexpression can induce apoptosis 105 |
| Spock2 | sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 | −26.545 | −12.428 | −7.20 | Upregulation of Spock2 inhibits migration and invasion of prostate cancer cells 106 |